Skip to main content

James Mahoney III, PhD

Assistant Professor/Clinical Neuropsychologist

Dr. Mahoney

304-598-4740 (p); 304-293-3766 (f)

Affiliations

Behavioral Medicine & Psychiatry; Blanchette Rockefeller Neurosciences Institute

Graduate Training

University of Houston, Ph.D. in Counseling Psychology. 2014; Pepperdine University (Los Angeles, CA), M.A., 2007

Fellowship

Clinical Neuropsychology Internship - University of Oklahoma Health Sciences Center; Clinical Neuropsychology Fellowship - University of Virginia


Links:

HSC directory listing

Dr. Mahoney's CV


Research Interests

My current research interests involve neuropsychological sequelae related to opioid use disorder and confounding/contributory factors impacting neurocognitive functioning in these individuals. I am also interested in the neurocircuitry of substance us disorders (SUD) and investigating novel treatments, such as repetitive transcranial magnetic stimulation (rTMS), for SUD. My current interests emerged from my previous research work as a Clinical Research Manager at the University of California, Los Angeles and the Baylor College of Medicine where the primary focus of the laboratories was Phase I medication development for stimulant use disorders. During this time, while the primary outcomes of the clinical trials were safety and initial efficacy of the medications, I was able to carve out my own niche that included evaluating whether these compounds impacted cognition as some of these agents had cognitive enhancing properties.


Research Topics:

  1. Investigating Novel Treatments for Opioid Use Disorder
  2. Neuropsychological Sequelae Associated with Opioid Use Disorder

Recent Publications

[2017]

  • Mahoney III JJ, Kalechstein AD, Newton TF, De La Garza II R. (2017) Cocaine use patterns do not impact neurocognitive functioning in individuals with cocaine use disorder. Journal of Psychopharmacology, 31, 989-995).
  • Mahoney III JJ, Haile CN, De La Garza II R, Thakkar H, Newton TF. (2017)  The relationship between heart rate and demographic/drug use variables in individuals with cocaine and methamphetamine use disorders. American Journal on Addictions, 26, 221-227.
  • Mahoney III JJ, De Marco AP, Aduen P, Langer J, Bajo SD, Broshek DK. (2017) The relationship between neuro-quality of life depression and anxiety measures and the Personality Assessment Inventory in persons with Epilepsy. Epilepsy and Behavior, 20, 145-149.
  • Mahoney III JJ, Bajo SD, De Marco AP, Arredondo BC, Broshek DK. (2017) Referring providers’ preferences and satisfaction with neuropsychological services. Archives of Clinical Neuropsychology, 32, 427-436.
  • Mahoney III JJ, Kalechstein AD, De Marco AP, Newton TF, De La Garza II R. (2017) The relationship between premorbid IQ and neurocognitive functioning in individuals with cocaine use disorders. Neuropsychology, 31, 311-318.

[2016]

  • De La Garza II R, Thompson-Lake D, Haile CN, Eisenhofer JD, Newton TF, Mahoney III JJ. (2016) Treadmill exercise improves fitness and reduces craving and use of cocaine, but not cigarettes, in individuals with concurrent cocaine and tobacco-use disorder. Psychiatry Research, 245, 133-140.
  • Copeland CT, Mahoney III JJ, Block CK, Linck JF, Pastorek NJ, Miller BI, Romesserd JM, Sim AH. (2016) Relative utility of performance and symptom validity tests. Archives of Clinical Neuropsychology, 31, 18-22.
  • De La Garza II R, Verrico C, Newton TF, Mahoney III JJ, Thompson-Lake D.(2016) Safety and preliminary efficacy of the acetylcholinesterase inhibitor huperzine A as a treatment for cocaine use disorder. The International Journal of Neuropsychopharmacology, 19, 1-9.
  • Logue E, Scarisbrick DM, Thaler NS, Mahoney III JJ, Block CK, Adams R, Scott J. (2016) Criterion validity of the WAIS-IV Cognitive Proficiency Index (CPI). The Clinical Neuropsychologist, 29, 777-787.

[2015]

  • Newton TF, Haile CN, Verrico CD, Mahoney III JJ, Shah R, Kosten TR, De La Garza II R. (2015) Dopamine D3 receptor-preferring agonist enhances the subjective effects of cocaine in humans. Neuropsychopharmacology, 153, 306-313.

Click here for additional publications.

Academic Honors

[2017]

  • West Virginia University School of Medicine – Chairman’s Research Award
  • American Psychological Association, Division 28 – Young Psychopharmacologist Award

[2016]

  • University of Virginia – Scientist-Practitioner Scholar Fellowship Award

[2013]

  • Association of Neuropsychology Students in Training – Member Highlight

[2012]

  • American College of Neuropsychopharmacology – Travel Award
  • American Psychological Association – Student Travel Award
  • University of Houston – APA Graduate Student Travel Award
  • American Psychological Association – NIDA/NIAAA Early Investigator Travel Award
  • College on Problems of Drug Dependence – Early Investigator Travel Award

[2011]

  • University of Texas – Medical Branch – Recipient of the Elizabeth Fitzgerald Sporar Endowment for Distinguished Initiatives in Addiction Research
  • American Psychological Association, Division 38 – Graduate Student Travel Award
  • University of Houston – APA Graduate Student Travel Award
  • American Psychological Association – 5th Annual Psychological Science Graduate Student Superstars Datablitz at APA Convention

[2003]

  • Bridgewater College, Outstanding Research Student of the Year